+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Intra-abdominal Infections Market by Antibiotic Class, Infection Type, Pathogen Type, Patient Age Group, End User, Distribution Channel - Global Forecast to 2030- Product Image
Intra-abdominal Infections Market by Antibiotic Class, Infection Type, Pathogen Type, Patient Age Group, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Intra-abdominal Infections Market by Antibiotic Class, Infection Type, Pathogen Type, Patient Age Group, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4905024
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Intra-abdominal Infections Market grew from USD 24.57 billion in 2024 to USD 26.86 billion in 2025. It is expected to continue growing at a CAGR of 8.97%, reaching USD 41.15 billion by 2030.

Unveiling the Complexity of Intra-abdominal Infections

Intra-abdominal infections represent some of the most challenging and multifaceted clinical conditions faced by healthcare systems worldwide. Arising from perforations, obstructions, or surgical interventions within the abdominal cavity, these infections can lead to severe complications such as sepsis and multiorgan failure when not managed promptly and effectively. The burden of intra-abdominal infections extends beyond acute care, as prolonged hospital stays, intensive antibiotic regimens, and the risk of recurrence place significant strain on providers, payers, and patients alike.

Recent years have witnessed an escalation in antimicrobial resistance among pathogens responsible for these infections, complicating treatment protocols and driving clinicians to adopt broader-spectrum or combination therapies. Concurrently, the rising prevalence of comorbidities such as diabetes and obesity has amplified patient susceptibility, demanding more nuanced clinical strategies. This introduction lays the foundation for understanding the evolving landscape of intra-abdominal infections and sets the stage for an in-depth exploration of market dynamics, policy impacts, and strategic imperatives.

Emerging Forces Reshaping the Infection Treatment Landscape

The landscape of intra-abdominal infection management is undergoing a profound transformation driven by scientific innovation, regulatory shifts, and changing patterns of bacterial resistance. Advances in rapid diagnostic technologies now enable more precise identification of causative agents, allowing clinicians to tailor antibiotic regimens with greater confidence. This precision medicine approach is complemented by an expanding pipeline of novel antimicrobial agents designed to circumvent known resistance mechanisms and improve patient outcomes.

At the same time, evolving healthcare policies are reshaping procurement and reimbursement models. Value-based care initiatives are incentivizing providers to focus on outcomes and optimize antibiotic stewardship programs, thereby reducing unnecessary usage and mitigating the emergence of resistant strains. Digital health platforms are emerging as critical tools for monitoring therapy adherence and tracking infection resolution, further reinforcing a shift toward data-driven, patient-centric models. These combined forces are not only redefining clinical practice but also creating new opportunities for stakeholders across the value chain.

Assessing the Impact of 2025 United States Tariffs on Drug Access

The introduction of United States tariffs on active pharmaceutical ingredients and finished antibiotic formulations in 2025 has injected fresh complexity into global supply chains. Raw material levies on key components have elevated production costs for manufacturers, prompting many to reassess sourcing strategies and evaluate the feasibility of nearshoring critical processes. As a result, the pharmaceutical industry is witnessing increased investment in local manufacturing capabilities to mitigate exposure to trade fluctuations and ensure continuity of supply.

These tariff measures have also had downstream effects on drug pricing and hospital procurement budgets. While some providers have passed marginal cost increases onto payers, others have negotiated long-term contracts to stabilize pricing and safeguard patient access. The net effect has been a recalibration of commercial strategies, with both multinational corporations and generic suppliers exploring collaborative ventures and licensing agreements to share risk and optimize distribution networks. Overall, the 2025 tariff landscape has underscored the need for agility and foresight in managing global antibiotic portfolios.

Critical Insights from Market Segmentation across Therapeutic and Demographic Dimensions

Understanding the intra-abdominal infection market requires a nuanced view of product and patient segments. Therapeutic classifications such as carbapenems, cephalosporins, and penicillins form the backbone of treatment regimens, with each class offering distinct efficacy profiles and resistance considerations. Within carbapenems, agents like doripenem, ertapenem, imipenem/cilastatin, and meropenem address a spectrum of Gram-negative and polymicrobial infections, while fourth-generation cephalosporins such as cefepime exhibit potent activity against resistant strains. Third-generation options including cefotaxime and ceftriaxone remain indispensable in many protocols, and beta-lactam/beta-lactamase inhibitor combinations like ampicillin/sulbactam and piperacillin/tazobactam continue to bridge gaps where monotherapy proves insufficient.

Infection origin further delineates treatment pathways: community-acquired cases, whether complicated or uncomplicated, often respond to outpatient-based regimens, whereas hospital-acquired scenarios demand ICU-associated and post-surgical protocols with higher-spectrum coverage. Pathogen-driven insights highlight the role of anaerobic bacteria, such as Bacteroides fragilis and Clostridium species, as well as key Gram-negative populations like Enterobacteriaceae and Pseudomonas aeruginosa. Gram-positive organisms, including Enterococcus species and Staphylococcus aureus, add another layer of complexity. Demographic factors reveal that adult patients constitute the largest cohort, though geriatric and pediatric subgroups present unique pharmacokinetic and safety considerations. Treatment settings range from ambulatory care centers to secondary and tertiary hospitals, each with distinct formulary preferences and stewardship frameworks. Finally, distribution channels encompassing hospital pharmacies, online dispensaries, and retail outlets determine access and influence prescribing behavior.

Regional Dynamics Driving Market Opportunities and Constraints

Regional dynamics exert a profound influence on treatment standards, reimbursement structures, and competitive intensity. In the Americas, integrated healthcare systems and robust reimbursement frameworks support broad access to both branded and generic antibiotics, driving innovation in stewardship and outcome-based contracting. The Europe, Middle East & Africa region exhibits a heterogeneous regulatory environment, where emerging markets invest in diagnostic infrastructure while mature economies emphasize cost containment and resistance surveillance.

Asia-Pacific stands out for its rapid adoption of advanced therapeutics, supported by expanding hospital networks and growing emphasis on antimicrobial stewardship. Local manufacturing hubs in several countries are bolstering supply security, and public-private partnerships are accelerating research initiatives tailored to regional pathogen profiles. Across all regions, collaborative efforts among government agencies, payers, and providers are increasingly essential to harmonize guidelines, improve clinical training, and address the unique challenges of intra-abdominal infection management.

Competitive Landscape and Strategic Positioning of Leading Players

The competitive landscape features a blend of established pharmaceutical giants and dynamic specialty players. Leading companies are differentiating through portfolio diversification, combining broad-spectrum antibiotics with targeted therapies designed for resistant infections. Strategic alliances and licensing agreements are proliferating as firms seek to augment their pipelines with innovative compounds developed by smaller biotech organizations.

In addition to product innovation, companies are investing in real-world evidence generation and post-approval studies to demonstrate comparative effectiveness and cost-efficiency. These initiatives are crucial for securing formulary inclusion and reimbursement in value-focused healthcare settings. Moreover, supply chain resilience has become a competitive differentiator, with firms leveraging geographic redundancy and advanced analytics to anticipate demand fluctuations and mitigate shortages. Business development activities continue to shape the landscape, as acquisitions and joint ventures expand geographic reach and reinforce therapeutic expertise.

Strategic Imperatives for Future-Proofing Treatment Pathways

Industry leaders must prioritize a set of strategic imperatives to maintain competitive advantage and drive sustainable growth. Implementing robust antibiotic stewardship protocols is paramount, ensuring that new and existing therapies are prescribed appropriately to preserve efficacy and prevent resistance. Investment in advanced diagnostics will enable earlier pathogen identification and therapy optimization, reducing hospital stays and improving patient outcomes.

Securing agile supply chains through diversified sourcing and localized manufacturing can shield operations from geopolitical and trade-related disruptions. Engaging proactively with regulatory bodies and payers will help shape favorable reimbursement pathways for innovative treatments. Collaboration with research institutions and participation in public-private partnerships can accelerate the development of next-generation antimicrobials. Finally, leveraging digital health solutions for remote monitoring and patient engagement will support adherence and enable data-driven decision making at every stage of the treatment journey.

Robust Methodological Framework Underpinning Our Analysis

The findings presented in this report are underpinned by a rigorous combination of primary and secondary research methodologies. Comprehensive literature reviews and regulatory database analyses were conducted to capture the latest developments in drug approvals, clinical trials, and stewardship guidelines. Expert interviews with key opinion leaders, clinicians, and industry executives enriched the qualitative perspective, while validation workshops ensured that emerging trends and strategic priorities were accurately represented.

Secondary data sources included proprietary databases, peer-reviewed journals, and public disclosures, all triangulated to ensure consistency and reliability. A systematic framework guided the synthesis of insights across therapeutic classes, infection types, and geographic regions. Quality control measures, including peer review and statistical validation, were applied to affirm the integrity of the analysis and support actionable conclusions.

Synthesis of Key Findings and Strategic Outlook

The analysis highlights a rapidly evolving intra-abdominal infection landscape, characterized by escalating resistance, shifting regulatory environments, and growing demand for precision medicine. Segmentation insights reveal differentiated growth drivers across therapeutic classes and patient cohorts, while regional nuances underscore the importance of tailored commercial strategies. Competitive positioning is increasingly defined by innovation in both product development and supply chain management, with partnerships and real-world evidence initiatives playing pivotal roles.

Looking ahead, stakeholders who embrace advanced diagnostics, strong stewardship programs, and agile operations will be best positioned to navigate complexity and deliver superior patient outcomes. By aligning strategic investments with emerging clinical needs and policy priorities, industry participants can unlock value and contribute meaningfully to the global fight against intra-abdominal infections.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Antibiotic Class
    • Carbapenems
      • Doripenem
      • Ertapenem
      • Imipenem/Cilastatin
      • Meropenem
    • Cephalosporins
      • Fourth Generation
        • Cefepime
      • Third Generation
        • Cefotaxime
        • Ceftriaxone
    • Penicillins
      • Ampicillin/Sulbactam
      • Piperacillin/Tazobactam
  • Infection Type
    • Community Acquired
      • Complicated
      • Uncomplicated
    • Hospital Acquired
      • ICU Associated
      • Post Surgical
  • Pathogen Type
    • Anaerobic
      • Bacteroides Fragilis
      • Clostridium Species
    • Gram Negative
      • Enterobacteriaceae
      • Pseudomonas Aeruginosa
    • Gram Positive
      • Enterococcus Species
      • Staphylococcus Aureus
  • Patient Age Group
    • Adult
    • Geriatric
    • Pediatric
  • End User
    • Ambulatory Care Centres
    • Hospitals
      • Secondary Care
      • Tertiary Care
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Merck & Co., Inc.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Allergan plc
  • GlaxoSmithKline plc
  • Shionogi & Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Intra-abdominal Infections Market, by Antibiotic Class
8.1. Introduction
8.2. Carbapenems
8.2.1. Doripenem
8.2.2. Ertapenem
8.2.3. Imipenem/Cilastatin
8.2.4. Meropenem
8.3. Cephalosporins
8.3.1. Fourth Generation
8.3.1.1. Cefepime
8.3.2. Third Generation
8.3.2.1. Cefotaxime
8.3.2.2. Ceftriaxone
8.4. Penicillins
8.4.1. Ampicillin/Sulbactam
8.4.2. Piperacillin/Tazobactam
9. Intra-abdominal Infections Market, by Infection Type
9.1. Introduction
9.2. Community Acquired
9.2.1. Complicated
9.2.2. Uncomplicated
9.3. Hospital Acquired
9.3.1. ICU Associated
9.3.2. Post Surgical
10. Intra-abdominal Infections Market, by Pathogen Type
10.1. Introduction
10.2. Anaerobic
10.2.1. Bacteroides Fragilis
10.2.2. Clostridium Species
10.3. Gram Negative
10.3.1. Enterobacteriaceae
10.3.2. Pseudomonas Aeruginosa
10.4. Gram Positive
10.4.1. Enterococcus Species
10.4.2. Staphylococcus Aureus
11. Intra-abdominal Infections Market, by Patient Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Intra-abdominal Infections Market, by End User
12.1. Introduction
12.2. Ambulatory Care Centres
12.3. Hospitals
12.3.1. Secondary Care
12.3.2. Tertiary Care
13. Intra-abdominal Infections Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. Americas Intra-abdominal Infections Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Intra-abdominal Infections Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Intra-abdominal Infections Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. Sandoz International GmbH
17.3.3. Teva Pharmaceutical Industries Ltd.
17.3.4. Viatris Inc.
17.3.5. Merck & Co., Inc.
17.3.6. Fresenius Kabi AG
17.3.7. Hikma Pharmaceuticals PLC
17.3.8. Allergan plc
17.3.9. GlaxoSmithKline plc
17.3.10. Shionogi & Co., Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. INTRA-ABDOMINAL INFECTIONS MARKET MULTI-CURRENCY
FIGURE 2. INTRA-ABDOMINAL INFECTIONS MARKET MULTI-LANGUAGE
FIGURE 3. INTRA-ABDOMINAL INFECTIONS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. INTRA-ABDOMINAL INFECTIONS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. INTRA-ABDOMINAL INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. INTRA-ABDOMINAL INFECTIONS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DORIPENEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ERTAPENEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY IMIPENEM/CILASTATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY MEROPENEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFEPIME, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFOTAXIME, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMPICILLIN/SULBACTAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PIPERACILLIN/TAZOBACTAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPLICATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY UNCOMPLICATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ICU ASSOCIATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY POST SURGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BACTEROIDES FRAGILIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLOSTRIDIUM SPECIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROCOCCUS SPECIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMBULATORY CARE CENTRES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SECONDARY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY TERTIARY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 98. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2030 (USD MILLION)
TABLE 99. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2030 (USD MILLION)
TABLE 100. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 101. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2030 (USD MILLION)
TABLE 102. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 103. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD MILLION)
TABLE 104. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 105. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2030 (USD MILLION)
TABLE 106. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2030 (USD MILLION)
TABLE 107. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 108. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2030 (USD MILLION)
TABLE 109. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2030 (USD MILLION)
TABLE 110. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2030 (USD MILLION)
TABLE 111. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 112. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 114. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2030 (USD MILLION)
TABLE 116. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2030 (USD MILLION)
TABLE 117. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 118. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2030 (USD MILLION)
TABLE 119. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 120. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD MILLION)
TABLE 121. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 122. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2030 (USD MILLION)
TABLE 123. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2030 (USD MILLION)
TABLE 124. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 125. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2030 (USD MILLION)
TABLE 126. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2030 (USD MILLION)
TABLE 127. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2030 (USD MILLION)
TABLE 128. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 129. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 131. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2030 (USD MILLION)
TABLE 202. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2030 (USD MILLION)
TABLE 203. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 204. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2030 (USD MILLION)
TABLE 205. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 206. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD MILLION)
TABLE 207. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 208. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2030 (USD MILLION)
TABLE 209. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2030 (USD MILLION)
TABLE 210. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 211. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2030 (USD MILLION)
TABLE 212. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2030 (USD MILLION)
TABLE 213. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2030 (USD MILLION)
TABLE 214. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 215. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 217. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2030 (USD MILLION)
TABLE 219. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2030 (USD MILLION)
TABLE 220. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 221. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2030 (USD MILLION)
TABLE 222. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 223. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD MILLION)
TABLE 224. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 225. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2030 (USD MILLION)
TABLE 226. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2030 (USD MILLION)
TABLE 227. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 228. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2030 (USD MILLION)
TABLE 229. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2030 (USD MILLION)
TABLE 230. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2030 (USD MILLION)
TABLE 231. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 232. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 234. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 238. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2030 (USD MILLION)
TABLE 239. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 240. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD MILLION)
TABLE 241. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 242. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2030 (USD MILLION)
TABLE 243. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2030 (USD MILLION)
TABLE 244. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 245. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2030 (USD MILLION)
TABLE 246. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2030 (USD MILLION)
TABLE 247. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2030 (USD MILLION)
TABLE 248. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 249. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 251. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2030 (USD MILLION)
TABLE 253. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2030 (USD MILLION)
TABLE 254. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 255. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2030 (USD MILLION)
TABLE 256. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 257. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD MILLION)
TABLE 258. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 259. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2030 (USD MILLION)
TABLE 260. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2030 (USD MILLION)
TABLE 261. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 262. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2030 (USD MILLION)
TABLE 263. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2030 (USD MILLION)
TABLE 264. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2030 (USD MILLION)
TABLE 265. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 266. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 268. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2030 (USD MILLION)
TABLE 270. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2030 (USD MILLION)
TABLE 271. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 272. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2030 (USD MILLION)
TABLE 273. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 274. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD MILLION)
TABLE 275. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 276. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2030 (USD MILLION)
TABLE 277. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2030 (USD MILLION)
TABLE 278. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 279. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2030 (USD MILLION)
TABLE 280. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2030 (USD MILLION)
TABLE 281. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2030 (USD MILLION)
TABLE 282. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 283. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 285. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2030 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2030 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2030 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2030 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2030 (USD MILLION)
TABLE 304. SAUDI ARABIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 306. SAUDI ARABIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2030 (USD MILLION)
TABLE 312. SAUDI ARABIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA INTRA-ABDOMINAL INFECTIONS

Companies Mentioned

The companies profiled in this Intra-abdominal Infections market report include:
  • Pfizer Inc.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Merck & Co., Inc.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Allergan plc
  • GlaxoSmithKline plc
  • Shionogi & Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 26.86 Billion
Forecasted Market Value ( USD ) by 2030 $ 41.15 Billion
Compound Annual Growth Rate8.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Complicated Intra-Abdominal Infections - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Complicated Intra-Abdominal Infections - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Complicated Intra-Abdominal Infections - Pipeline Insight, 2025 - Product Image

Complicated Intra-Abdominal Infections - Pipeline Insight, 2025

  • Clinical Trials
  • 50 Pages
  • Global
From
Microbiology for Surgical Infections. Diagnosis, Prognosis and Treatment - Product Image

Microbiology for Surgical Infections. Diagnosis, Prognosis and Treatment

  • Book
Multidrug Resistant Bacteria Market Report 2025 - Product Image

Multidrug Resistant Bacteria Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Ceftriaxone - Global Strategic Business Report - Product Image

Ceftriaxone - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.